Homburger advised the shareholders of Evax AG on the sale to Boehringer Ingelheim, Switzerland; Acquisition completed July 24, 2026
Homburger advised the shareholders of Evax AG on the sale to Boehringer Ingelheim, Switzerland; Acquisition completed July 24, 2026 Homburger advised the shareholders of Evax AG on the sale to Boehringer Ingelheim Homburger advised the shareholders of Evax AG on the sale to Boehringer Ingelheim On July 24, 2026, Boehringer Ingelheim acquired Evax AG, a Swiss biotech company focused on equine health. Founded more than a decade ago at the University of Zurich, Evax has been exploring the use of therapeutic vaccines to address significant unmet needs in horses, particularly for the treatment of allergic skin diseases. ...